- NCIt
- C115334
Loading cancer entity…
Loading cancer entity…
Clinical trials
9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | terminated | Phase 2 | 32 | University of ChicagoOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium |
| terminated |
| Phase 2 |
| 27 |
| National Cancer Institute (NCI)NIH |
| 1 |
| May 30, 2014 |
| clinicaltrials |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Apr 25, 2025source: clinicaltrials